CymaBay Therapeutics (CBAY) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month target prices for CymaBay Therapeutics' stock. Their CBAY share price forecasts range from $12.00 to $19.00. On average, they anticipate the company's share price to reach $14.57 in the next twelve months. This suggests a possible upside of 54.9% from the stock's current price.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.

CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 50.1% and is now trading at $9.41.
View the best growth stocks for 2023 here.

CymaBay Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 10,130,000 shares, a drop of 8.5% from the April 30th total of 11,070,000 shares. Based on an average trading volume of 1,700,000 shares, the days-to-cover ratio is presently 6.0 days.
View CymaBay Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our CBAY earnings forecast.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings data on Thursday, March, 16th. The biopharmaceutical company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). During the same quarter in the previous year, the business earned ($0.34) earnings per share.

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Raymond James SB-1 Equity ETF (RYJ), ALPS Medical Breakthroughs ETF (SBIO) and iShares Micro-Cap ETF (IWC).

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

CymaBay Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (4.01%), Franklin Resources Inc. (3.31%), BlackRock Inc. (2.72%), Bain Capital Life Sciences Investors LLC (2.57%), Commodore Capital LP (2.08%) and Balyasny Asset Management L.P. (2.01%). Insiders that own company stock include Charles Mcwherter, Dennis D Kim, Paul T Quinlan and Sujal Shah.
View institutional ownership trends.

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CBAY stock can currently be purchased for approximately $9.41.

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $917.60 million. The biopharmaceutical company earns $-106,000,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.